BMX Inhibitors
1 drugsAbout BMX
BMX (bone marrow tyrosine kinase gene in chromosome X) is a non-receptor tyrosine kinase involved in intracellular signaling pathways. As a kinase, BMX modulates protein activity by adding phosphate groups, influencing cellular processes.
Currently, there is no genetic evidence directly linking BMX to specific diseases, but its role in intracellular signaling makes it a potential target for drug development.
BMX is targeted by one FDA-approved drug, RHAPSIDO (small molecule), developed by Novartis for one indication.
Top BMX Drugs
Novartis is the only company with an approved drug (RHAPSIDO) targeting BMX.
The lack of competitors suggests high barriers to entry or untapped potential in the BMX space.
BMX Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BMX, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
BMX Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BMX. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 3 | 0 | 1 | 2 | 0% |
| Phase 3 | 16 | 0 | 0 | 16 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved BMX drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BMX. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BMX Drug Approval Timeline (2025 - 2025)
The first and most recent drug approval for BMX was RHAPSIDO in 2025.
The recent approval suggests renewed interest, but further approvals are needed to confirm sustained therapeutic value.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BMX. A trial counts if an approved drug acting on BMX is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.